查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
勃起功能障碍 (ED) 药物市场：成长、未来展望与竞争分析（2025-2033 年）
市场调查报告书
商品编码
1675076

勃起功能障碍 (ED) 药物市场：成长、未来展望与竞争分析（2025-2033 年）

Erectile Dysfunction (ED) Drugs Market - Growth, Future Prospects and Competitive Analysis, 2025 - 2033
出版日期: | 出版商: Acute Market Reports | 英文 171 Pages | 商品交期: 最快1-2个工作天内

价格

勃起功能障碍（ED）药物是用于治疗勃起功能障碍的药物－勃起功能障碍的特征是无法达到或维持足以进行令人满意的性活动的勃起。治疗勃起功能障碍的药物通常会透过增加流向阴茎的血流量来发挥作用，主要是透过抑制调节血管扩张的某些酵素。最常见的治疗 ED 药物包括 5 型磷酸二酯酶抑制剂 (PDE5 抑制剂)，但根据患者的健康状况和功能障碍的根本原因，也会使用其他类别的药物。勃起功能障碍药物市场预计将以 3.2% 的复合年增长率 (CAGR) 成长。推动这种增长的因素是糖尿病、高血压和荷尔蒙失调等疾病的发病率不断上升，这些疾病通常与 ED 的发展有关。

世界人口老化

勃起功能障碍（ED）药物市场的主要驱动力是世界人口老化。随着已开发国家和新兴国家人口老化，糖尿病、高血压、心血管疾病等慢性病的发生率将会增加，而这些慢性病是导致ED的重要危险因子。年龄是影响 ED 盛行率的重要人口因素，40 多岁的男性中约有 5% 患有 ED，65 岁以上的男性中约有 15-25% 患有 ED。由于老龄化人口寻求解决方案以维持令人满意的生活质量，这种人口趋势正在推动对 ED 药物的需求。老年人的预期寿命不断增加以及他们对积极生活方式的渴望进一步推动了这种需求，越来越多的人希望解决影响他们健康和生活品质的健康问题。

远端医疗及网路药局

远端医疗和网路药局的兴起为 ED 药物市场带来了巨大的机会。远端医疗的进步使患者能够获得更个人化和便捷的咨询，这对于患有勃起功能障碍（ED）等带有社会耻辱的疾病尤其重要。线上平台可以为患者提供一条谨慎的治疗途径，并增强他们治疗和控制疾病的动机。此外，网路药局改善了人们获得治疗勃起功能障碍药物的管道，扩大了市场覆盖范围，尤其是在农村和服务不足的地区。此类平台通常提供更好的定价模式和可近性，使治疗选择更实惠、更快捷，从而有可能提高市场渗透率和患者对处方治疗的依从性。

专利到期

治疗勃起功能障碍的药物市场的主要限制因素是主要畅销药物的专利到期。当专利到期后，学名药就会进入市场，大大降低品牌药製造商的价格和收益。例如，Sildenafil（威而钢）非专利药的推出大大降低了患者的治疗费用，但同时也减少了品牌药製造商辉瑞的市场占有率和收益。学名药虽然提高了药品的可用性和可负担性，但同时也降低了品牌药市场现有参与者的利润率，加剧了竞争，并抑制了新治疗方法的创新。

监管和安全问题

勃起功能障碍药物市场面临的主要挑战之一是应对严格的法规环境并解决与勃起功能障碍药物相关的安全问题。治疗 ED 的药物可能会产生严重的副作用，并且会与其他药物相互作用，而硝酸盐（尤其是用于治疗心臟病的硝酸盐）可能会导致血压危险下降。在开发新配方的同时确保患者安全需要进行大量的临床试验和严格的安全测试，这既昂贵又耗时。此外，获得新药监管部门的核准需要严格的流程，涉及多个阶段的测试以证明其功效和安全性。这些障碍对 ED 治疗领域的製药公司构成了挑战，因为它们减缓了新产品的市场推出速度并涉及大量的财务投资。

药品市场区隔

勃起功能障碍 (ED) 药物市场按药物类型细分为威而钢、希爱力、Staxyn/艾力达、Stendra/Spedra 和其他。威而钢（Sildenafil）是 20 世纪 90 年代末首个核准治疗勃起功能障碍的口服药物，由于它是一个成熟的品牌，因此它一直是该类别中销量最高的药物。它的高度认可度和丰富的临床记录使其成为患者和医疗保健提供者的首选。不过，预计希爱力（他达拉非）未来的复合年增长率最高。这一预计增长是由于西力士的半衰期较长，从而具有更大的自发性，这是与竞争药物的关键区别。此外，西力士的每日一次配方选择提高了患者的依从性和满意度，使其不仅作为治疗 ED 的方法越来越受欢迎，而且作为治疗文明病的方法也越来越受欢迎。

按分销通路细分市场

根据分销管道，勃起功能障碍药物市场细分为医院药房、零售药房和线上药房。目前，零售药局凭藉其药品可及性广、便利性等优势，成为此领域收益最高的产业。许多患者更愿意从零售药局购买治疗勃起功能障碍的药物，因为在那里他们也可以得到药师的建议和支持。相反，预计在 2025 年至 2033 年期间，网上药局的复合年增长率最高。这种成长的推动因素是消费者对隐私和便利性的偏好增强，以及线上平台通常提供的具有竞争力的定价模式。远端医疗服务的兴起也推动了网路药局的发展，越来越多的患者在网路上取处方笺并选择宅配服务，使得透过这些管道购买勃起功能障碍药物更具吸引力且更加方便。

勃起功能障碍 (ED) 治疗药物市场的区域趋势

勃起功能障碍药物市场呈现出明显的区域趋势，其中北美在 2024 年的销售额方面处于领先地位。这是由于该地区的医疗费用高昂、人们对 ED 治疗的认识普遍提高以及大型企业的存在。此外，先进的医疗保健基础设施以及导致 ED 的糖尿病和高血压等生活方式相关健康问题的高度流行，支撑了北美强劲的市场需求。然而，预计亚太地区在 2025 年至 2033 年期间的复合年增长率最高。这种成长背后的因素包括医疗保健意识的增强、可支配收入的增加以及这些社会对讨论性健康问题的耻辱感的逐渐消除。此外，这些市场中医疗保健体系的不断扩大和 ED 药物供应的不断增加预计将推动显着增长。

竞争趋势和关键策略

2024 年，勃起功能障碍药物市场的竞争格局将由主要企业公司、礼来公司、拜耳公司、Vivs 和 Teva Pharmaceutical Industries, Inc. 以及东亚 ST Corporation、SK Chemicals、Meda Pharmaceuticals, Inc.、Crystalia Produtos Kymikos Farmaceutikos、Apricus Biosciences Inc. 和参与者的主要倡议所决定的策略倡议所决定。这些公司正广泛致力于研究和开发，以推出更有效、更安全的 ED 药物。辉瑞公司和礼来公司分别拥有标誌性产品威而钢和希爱力，并透过保持强大的品牌忠诚度和广泛的全球分销网络主导了市场。旨在减少副作用和提高患者便利性的创新，如起效更快的製剂和学名药，是关注领域。 2025 年至 2033 年间，我们预计这些公司将加强实现产品组合多元化，包括探索针对荷尔蒙失衡和血管健康等潜在疾病（而不仅仅是症状）的 ED治疗方法。策略伙伴关係，特别是对于全球扩张和进入新兴市场而言，可能极为重要。此外，网路药局的趋势可能会鼓励这些公司加强其数位策略，以覆盖更广泛的客户群。随着公司适应不断变化的消费行为和日益激烈的市场竞争，对竞争性定价、病患教育计画和远端医疗平台的投资预计将成为关键。

目录

第 1 章 简介

  • 分析内容
    • 分析目的
    • 目标受众
    • 主要产品
  • 市场区隔
  • 分析方法
    • 第一阶段：二次研究
    • 第二阶段：初步调查
    • 第三阶段：专家评审
    • 先决条件
    • 采取的方法

第 2 章执行摘要

3. 勃起功能障碍 (ED) 药物市场：竞争分析

  • 主要供应商的市场定位
  • 供应商所采用的策略
  • 重大产业战略

4. 勃起功能障碍 (ED) 药物市场：宏观分析与市场动态

  • 介绍
  • 2023 年至 2033 年全球勃起功能障碍 (ED) 药物市场以金额为准
  • 市场动态
    • 市场驱动因素
    • 市场限制
    • 主要挑战
    • 主要机会
  • 驱动因素与限制因素影响分析
  • 跷跷板分析
  • 波特五力模型
    • 供应商权力
    • 购买者力量
    • 替代品的威胁
    • 新进入者的威胁
    • 竞争对手之间的竞争
  • PESTEL 分析
    • 政局
    • 经济情势
    • 技术状况
    • 法律状况
    • 社会状况

5. 勃起功能障碍 (ED) 药物市场（依药物类型划分） (2023-2033)

  • 市场概况
  • 成长与收益分析：2024 年 vs 2033 年
  • 市场区隔
    • 威而钢
    • 希爱力
    • Staxyn/Levitra
    • 斯特德拉/斯佩德拉
    • 其他的

6. 勃起功能障碍 (ED) 药物市场依分销管道划分（2023-2033 年）

  • 市场概况
  • 成长与收益分析：2024 年 vs 2033 年
  • 市场区隔
    • 医院药房
    • 零售药局
    • 网路药局

7. 北美勃起功能障碍 (ED) 药物市场（2023-2033 年）

  • 市场概况
  • 勃起功能障碍 (ED) 药物市场（按药物类型划分） (2023-2033)
  • 勃起功能障碍 (ED) 药物市场按分销管道划分（2023-2033 年）
  • 勃起功能障碍 (ED) 药物市场（按地区） (2023-2033)
    • 北美洲
      • 美国
      • 加拿大
      • 北美其他地区

8.英国和欧盟勃起功能障碍 (ED) 药物市场（2023-2033 年）

  • 市场概况
  • 勃起功能障碍 (ED) 药物市场（按药物类型划分） (2023-2033)
  • 勃起功能障碍 (ED) 药物市场按分销管道划分（2023-2033 年）
  • 勃起功能障碍 (ED) 药物市场（按地区） (2023-2033)
    • 英国和欧盟国家
      • 英国
      • 德国
      • 西班牙
      • 义大利
      • 法国
      • 其他欧洲国家地区

9. 亚太地区勃起功能障碍 (ED) 药物市场（2023-2033 年）

  • 市场概况
  • 勃起功能障碍 (ED) 药物市场（按药物类型划分） (2023-2033)
  • 勃起功能障碍 (ED) 药物市场按分销管道划分（2023-2033 年）
  • 勃起功能障碍 (ED) 药物市场（按地区） (2023-2033)
    • 亚太地区
      • 中国
      • 日本
      • 印度
      • 澳洲
      • 韩国
      • 其他亚太地区

10. 拉丁美洲勃起功能障碍 (ED) 药物市场（2023-2033 年）

  • 市场概况
  • 勃起功能障碍 (ED) 药物市场（按药物类型划分） (2023-2033)
  • 勃起功能障碍 (ED) 药物市场按分销管道划分（2023-2033 年）
  • 勃起功能障碍 (ED) 药物市场（按地区） (2023-2033)
    • 拉丁美洲
      • 巴西
      • 墨西哥
      • 其他拉丁美洲国家

11. 中东和非洲勃起功能障碍 (ED) 药物市场（2023-2033 年）

  • 市场概况
  • 勃起功能障碍 (ED) 药物市场（按药物类型划分） (2023-2033)
  • 勃起功能障碍 (ED) 药物市场按分销管道划分（2023-2033 年）
  • 勃起功能障碍 (ED) 药物市场（按地区） (2023-2033)
    • 中东和非洲
      • GCC
      • 非洲
      • 其他中东和非洲地区

第十二章 公司简介

  • Pfizer Inc.
  • Dong-A ST Co. Ltd.
  • Eli Lilly and Company
  • Bayer AG
  • Vivus Inc.
  • Teva Pharmaceutical Industries Ltd.
  • SK Chemicals
  • Meda Pharmaceuticals Inc.
  • Cristalia Produtos Quimicos Farmaceuticos Ltda. Apricus Biosciences Inc.
  • Futura Medical plc
  • 其他知名公司
Product Code: 20042-01-25

Erectile Dysfunction (ED) drugs are pharmaceutical agents used to treat erectile dysfunction, a condition characterized by the inability to achieve or maintain an erection sufficient for satisfactory sexual performance. ED drugs generally work by increasing blood flow to the penis, predominantly through the inhibition of specific enzymes that regulate blood vessel dilation. The most common class of ED drugs includes phosphodiesterase type 5 inhibitors (PDE5 inhibitors), but other drug classes are also used depending on the patient's health profile and the underlying cause of the dysfunction. The erectile dysfunction drugs market is projected to grow at a Compound Annual Growth Rate (CAGR) of 3.2%. This growth is driven by an increasing incidence of conditions such as diabetes, hypertension, and hormonal imbalances, which are often linked to the development of ED.

Aging Global Population

A primary driver for the erectile dysfunction (ED) drugs market is the globally aging population. As populations in developed and developing countries age, the incidence of chronic conditions such as diabetes, hypertension, and cardiovascular diseases-which are significant risk factors for ED-increases. Age is a strong demographic factor in ED prevalence; the condition affects about 5% of men in their 40s and 15-25% of men by the age of 65. This demographic trend is pushing demand for ED medications as older populations seek solutions to maintain a satisfactory quality of life. The increasing life expectancy and desire for an active lifestyle among older adults further fuel this demand, as more individuals seek to address health issues that affect their well-being and lifestyle quality.

Telemedicine and Online Pharmacies

The rise of telemedicine and online pharmacies presents a significant opportunity in the ED drugs market. With advancements in telehealth, patients can now have more private and convenient consultations, which is particularly important for conditions with social stigmas like ED. Online platforms provide discreet avenues for patients to seek treatment, which can increase the willingness to address and manage this condition. Furthermore, online pharmacies improve access to ED medications, especially in rural or underserved areas, broadening the market reach. These platforms often provide better pricing models and accessibility, making treatment options more affordable and prompt, thus potentially increasing market penetration and patient adherence to prescribed therapies.

Patent Expirations

A major restraint in the ED drugs market is the expiration of patents for key blockbuster drugs. As patents expire, generic versions enter the market, leading to a significant reduction in prices and revenue for the original drug manufacturers. For instance, the introduction of generic versions of sildenafil (Viagra) has dramatically decreased costs for patients but has also reduced the market share and revenue for Pfizer, the original manufacturer. While generics increase accessibility and affordability, they also thin profit margins for existing players in the branded pharmaceutical market, intensifying competition and putting pressure on the innovation of new therapies.

Regulatory and Safety Concerns

One of the significant challenges facing the ED drugs market is navigating the stringent regulatory environment and addressing safety concerns associated with these medications. ED drugs can have serious side effects and interactions with other medications, particularly nitrates used for heart disease, which can lead to unsafe drops in blood pressure. Ensuring patient safety while developing new formulations requires extensive clinical trials and robust safety studies, which are costly and time-consuming. Additionally, gaining regulatory approval for new drugs is a rigorous process, involving multiple phases of testing to prove efficacy and safety. These barriers can delay the introduction of new products to the market and involve substantial financial investment, presenting a challenge for pharmaceutical companies in the ED drugs sector.

Market Segmentation by Drug

In the erectile dysfunction (ED) drugs market, segmentation by drug includes Viagra, Cialis, Staxyn/Levitra, Stendra/Spedra, and Others. Viagra (sildenafil citrate) historically holds the highest revenue within this segment due to its well-established brand, being the first approved oral treatment for ED in the late 1990s. Its widespread recognition and extensive clinical history have made it a preferred choice among patients and healthcare providers alike. However, Cialis (tadalafil) is expected to experience the highest CAGR moving forward. This anticipated growth is attributed to Cialis's longer half-life, which allows for greater spontaneity and has been a key differentiator from its competitors. Cialis's once-daily formulation option also enhances patient adherence and satisfaction, making it increasingly popular as a lifestyle drug beyond just the treatment of ED.

Market Segmentation by Distribution Channel

The market segmentation by distribution channel in the ED drugs market includes Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies. Retail pharmacies currently generate the highest revenue in this segment, benefiting from widespread accessibility and the convenience of obtaining medication. Many patients prefer purchasing their ED medications from retail pharmacies, where they can also seek advice and support from pharmacists. Conversely, Online Pharmacies are projected to witness the highest CAGR from 2025 to 2033. This growth is driven by the increasing consumer preference for privacy and convenience, coupled with competitive pricing models that online platforms often offer. The rise of telehealth services has also facilitated the growth of online pharmacies, as more patients receive prescriptions online and opt for home delivery services, enhancing the appeal and accessibility of purchasing ED medications through these channels.

Geographic Trends in the Erectile Dysfunction (ED) Drugs Market

The erectile dysfunction drugs market demonstrates distinct geographic trends, with North America leading in revenue generation in 2024. This is attributed to the region's high healthcare expenditure, widespread awareness of ED treatments, and the presence of key market players. Additionally, the advanced healthcare infrastructure and high prevalence of lifestyle-related health issues that contribute to ED, such as diabetes and hypertension, support robust market demand in North America. However, the Asia-Pacific region is expected to experience the highest CAGR from 2025 to 2033. Factors contributing to this growth include increasing healthcare awareness, rising disposable incomes, and the gradual destigmatization of discussing sexual health issues in these societies. Moreover, the expansion of healthcare systems and the increasing availability of ED medications in these markets are expected to drive significant growth.

Competitive Trends and Key Strategies

In 2024, the competitive landscape of the ED drugs market was shaped by strategic initiatives from leading players such as Pfizer, Inc., Eli Lilly and Company, Bayer AG, Vivus, Inc., Teva Pharmaceutical Industries Ltd., and others including Dong-A ST Co., Ltd., SK Chemicals, Meda Pharmaceuticals, Inc., Cristalia Produtos Quimicos Farmaceuticos Ltda., Apricus Biosciences, Inc., and Futura Medical plc. These companies focused extensively on research and development to introduce more effective and safer ED treatments. Pfizer and Eli Lilly, holding seminal products like Viagra and Cialis, respectively, dominated the market by maintaining strong brand loyalty and extensive global distribution networks. Innovations aimed at reducing side effects and enhancing patient convenience, such as fast-acting formulations and generics, were key areas of focus. From 2025 to 2033, these companies are expected to intensify their efforts towards diversification of their portfolios, including the exploration of ED treatments that address underlying conditions like hormonal imbalances or vascular health, beyond just the symptoms. Strategic partnerships, especially for global expansion and tapping into emerging markets, will likely be crucial. Moreover, the ongoing trend towards online pharmacies will prompt these companies to enhance their digital strategies to reach a broader customer base. Competitive pricing, patient education programs, and investments in telemedicine platforms are expected to be significant as companies adapt to changing consumer behaviors and increased market competition.

Historical & Forecast Period

This study report represents an analysis of each segment from 2023 to 2033 considering 2024 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2025 to 2033.

The current report comprises quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends & technological analysis, case studies, strategic conclusions and recommendations and other key market insights.

Research Methodology

The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. The key data points that enable the estimation of Erectile Dysfunction (ED) Drugs market are as follows:

Research and development budgets of manufacturers and government spending

Revenues of key companies in the market segment

Number of end users & consumption volume, price, and value.

Geographical revenues generated by countries considered in the report

Micro and macro environment factors that are currently influencing the Erectile Dysfunction (ED) Drugs market and their expected impact during the forecast period.

Market forecast was performed through proprietary software that analyzes various qualitative and quantitative factors. Growth rate and CAGR were estimated through intensive secondary and primary research. Data triangulation across various data points provides accuracy across various analyzed market segments in the report. Application of both top-down and bottom-up approach for validation of market estimation assures logical, methodical, and mathematical consistency of the quantitative data.

  • Market Segmentation
    • Drug
  • Viagra
  • Cialis
  • Staxyn/Levitra
  • Stendra/Spedra
  • Others
    • Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Region Segment (2023-2033; US$ Million)
  • North America
  • U.S.
  • Canada
  • Rest of North America
  • UK and European Union
  • UK
  • Germany
  • Spain
  • Italy
  • France
  • Rest of Europe
  • Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of Asia Pacific
  • Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
  • Middle East and Africa
  • GCC
  • Africa
  • Rest of Middle East and Africa

Key questions answered in this report

  • What are the key micro and macro environmental factors that are impacting the growth of Erectile Dysfunction (ED) Drugs market?
  • What are the key investment pockets concerning product segments and geographies currently and during the forecast period?
  • Estimated forecast and market projections up to 2033.
  • Which segment accounts for the fastest CAGR during the forecast period?
  • Which market segment holds a larger market share and why?
  • Are low and middle-income economies investing in the Erectile Dysfunction (ED) Drugs market?
  • Which is the largest regional market for Erectile Dysfunction (ED) Drugs market?
  • What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East & Africa?
  • Which are the key trends driving Erectile Dysfunction (ED) Drugs market growth?
  • Who are the key competitors and what are their key strategies to enhance their market presence in the Erectile Dysfunction (ED) Drugs market worldwide?

Table of Contents

1. Preface

  • 1.1. Report Description
    • 1.1.1. Purpose of the Report
    • 1.1.2. Target Audience
    • 1.1.3. Key Offerings
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
    • 1.3.1. Phase I - Secondary Research
    • 1.3.2. Phase II - Primary Research
    • 1.3.3. Phase III - Expert Panel Review
    • 1.3.4. Assumptions
    • 1.3.5. Approach Adopted

2. Executive Summary

  • 2.1. Market Snapshot: Global Erectile Dysfunction (ED) Drugs Market
  • 2.2. Global Erectile Dysfunction (ED) Drugs Market, By Drug, 2024 (US$ Million)
  • 2.3. Global Erectile Dysfunction (ED) Drugs Market, By Distribution Channel, 2024 (US$ Million)
  • 2.4. Global Erectile Dysfunction (ED) Drugs Market, By Geography, 2024 (US$ Million)
  • 2.5. Attractive Investment Proposition by Geography, 2024

3. Erectile Dysfunction (ED) Drugs Market: Competitive Analysis

  • 3.1. Market Positioning of Key Erectile Dysfunction (ED) Drugs Market Vendors
  • 3.2. Strategies Adopted by Erectile Dysfunction (ED) Drugs Market Vendors
  • 3.3. Key Industry Strategies

4. Erectile Dysfunction (ED) Drugs Market: Macro Analysis & Market Dynamics

  • 4.1. Introduction
  • 4.2. Global Erectile Dysfunction (ED) Drugs Market Value, 2023 - 2033, (US$ Million)
  • 4.3. Market Dynamics
    • 4.3.1. Market Drivers
    • 4.3.2. Market Restraints
    • 4.3.3. Key Challenges
    • 4.3.4. Key Opportunities
  • 4.4. Impact Analysis of Drivers and Restraints
  • 4.5. See-Saw Analysis
  • 4.6. Porter's Five Force Model
    • 4.6.1. Supplier Power
    • 4.6.2. Buyer Power
    • 4.6.3. Threat Of Substitutes
    • 4.6.4. Threat Of New Entrants
    • 4.6.5. Competitive Rivalry
  • 4.7. PESTEL Analysis
    • 4.7.1. Political Landscape
    • 4.7.2. Economic Landscape
    • 4.7.3. Technology Landscape
    • 4.7.4. Legal Landscape
    • 4.7.5. Social Landscape

5. Erectile Dysfunction (ED) Drugs Market: By Drug, 2023-2033, USD (Million)

  • 5.1. Market Overview
  • 5.2. Growth & Revenue Analysis: 2024 Versus 2033
  • 5.3. Market Segmentation
    • 5.3.1. Viagra
    • 5.3.2. Cialis
    • 5.3.3. Staxyn/Levitra
    • 5.3.4. Stendra/Spedra
    • 5.3.5. Others

6. Erectile Dysfunction (ED) Drugs Market: By Distribution Channel, 2023-2033, USD (Million)

  • 6.1. Market Overview
  • 6.2. Growth & Revenue Analysis: 2024 Versus 2033
  • 6.3. Market Segmentation
    • 6.3.1. Hospital Pharmacies
    • 6.3.2. Retail Pharmacies
    • 6.3.3. Online Pharmacies

7. North America Erectile Dysfunction (ED) Drugs Market, 2023-2033, USD (Million)

  • 7.1. Market Overview
  • 7.2. Erectile Dysfunction (ED) Drugs Market: By Drug, 2023-2033, USD (Million)
  • 7.3. Erectile Dysfunction (ED) Drugs Market: By Distribution Channel, 2023-2033, USD (Million)
  • 7.4.Erectile Dysfunction (ED) Drugs Market: By Region, 2023-2033, USD (Million)
    • 7.4.1.North America
      • 7.4.1.1. U.S.
        • 7.4.1.1.1. Erectile Dysfunction (ED) Drugs Market: By Drug, 2023-2033, USD (Million)
        • 7.4.1.1.2. Erectile Dysfunction (ED) Drugs Market: By Distribution Channel, 2023-2033, USD (Million)
      • 7.4.1.2. Canada
        • 7.4.1.2.1. Erectile Dysfunction (ED) Drugs Market: By Drug, 2023-2033, USD (Million)
        • 7.4.1.2.2. Erectile Dysfunction (ED) Drugs Market: By Distribution Channel, 2023-2033, USD (Million)
      • 7.4.1.3. Rest of North America
        • 7.4.1.3.1. Erectile Dysfunction (ED) Drugs Market: By Drug, 2023-2033, USD (Million)
        • 7.4.1.3.2. Erectile Dysfunction (ED) Drugs Market: By Distribution Channel, 2023-2033, USD (Million)

8. UK and European Union Erectile Dysfunction (ED) Drugs Market, 2023-2033, USD (Million)

  • 8.1. Market Overview
  • 8.2. Erectile Dysfunction (ED) Drugs Market: By Drug, 2023-2033, USD (Million)
  • 8.3. Erectile Dysfunction (ED) Drugs Market: By Distribution Channel, 2023-2033, USD (Million)
  • 8.4.Erectile Dysfunction (ED) Drugs Market: By Region, 2023-2033, USD (Million)
    • 8.4.1.UK and European Union
      • 8.4.1.1. UK
        • 8.4.1.1.1. Erectile Dysfunction (ED) Drugs Market: By Drug, 2023-2033, USD (Million)
        • 8.4.1.1.2. Erectile Dysfunction (ED) Drugs Market: By Distribution Channel, 2023-2033, USD (Million)
      • 8.4.1.2. Germany
        • 8.4.1.2.1. Erectile Dysfunction (ED) Drugs Market: By Drug, 2023-2033, USD (Million)
        • 8.4.1.2.2. Erectile Dysfunction (ED) Drugs Market: By Distribution Channel, 2023-2033, USD (Million)
      • 8.4.1.3. Spain
        • 8.4.1.3.1. Erectile Dysfunction (ED) Drugs Market: By Drug, 2023-2033, USD (Million)
        • 8.4.1.3.2. Erectile Dysfunction (ED) Drugs Market: By Distribution Channel, 2023-2033, USD (Million)
      • 8.4.1.4. Italy
        • 8.4.1.4.1. Erectile Dysfunction (ED) Drugs Market: By Drug, 2023-2033, USD (Million)
        • 8.4.1.4.2. Erectile Dysfunction (ED) Drugs Market: By Distribution Channel, 2023-2033, USD (Million)
      • 8.4.1.5. France
        • 8.4.1.5.1. Erectile Dysfunction (ED) Drugs Market: By Drug, 2023-2033, USD (Million)
        • 8.4.1.5.2. Erectile Dysfunction (ED) Drugs Market: By Distribution Channel, 2023-2033, USD (Million)
      • 8.4.1.6. Rest of Europe
        • 8.4.1.6.1. Erectile Dysfunction (ED) Drugs Market: By Drug, 2023-2033, USD (Million)
        • 8.4.1.6.2. Erectile Dysfunction (ED) Drugs Market: By Distribution Channel, 2023-2033, USD (Million)

9. Asia Pacific Erectile Dysfunction (ED) Drugs Market, 2023-2033, USD (Million)

  • 9.1. Market Overview
  • 9.2. Erectile Dysfunction (ED) Drugs Market: By Drug, 2023-2033, USD (Million)
  • 9.3. Erectile Dysfunction (ED) Drugs Market: By Distribution Channel, 2023-2033, USD (Million)
  • 9.4.Erectile Dysfunction (ED) Drugs Market: By Region, 2023-2033, USD (Million)
    • 9.4.1.Asia Pacific
      • 9.4.1.1. China
        • 9.4.1.1.1. Erectile Dysfunction (ED) Drugs Market: By Drug, 2023-2033, USD (Million)
        • 9.4.1.1.2. Erectile Dysfunction (ED) Drugs Market: By Distribution Channel, 2023-2033, USD (Million)
      • 9.4.1.2. Japan
        • 9.4.1.2.1. Erectile Dysfunction (ED) Drugs Market: By Drug, 2023-2033, USD (Million)
        • 9.4.1.2.2. Erectile Dysfunction (ED) Drugs Market: By Distribution Channel, 2023-2033, USD (Million)
      • 9.4.1.3. India
        • 9.4.1.3.1. Erectile Dysfunction (ED) Drugs Market: By Drug, 2023-2033, USD (Million)
        • 9.4.1.3.2. Erectile Dysfunction (ED) Drugs Market: By Distribution Channel, 2023-2033, USD (Million)
      • 9.4.1.4. Australia
        • 9.4.1.4.1. Erectile Dysfunction (ED) Drugs Market: By Drug, 2023-2033, USD (Million)
        • 9.4.1.4.2. Erectile Dysfunction (ED) Drugs Market: By Distribution Channel, 2023-2033, USD (Million)
      • 9.4.1.5. South Korea
        • 9.4.1.5.1. Erectile Dysfunction (ED) Drugs Market: By Drug, 2023-2033, USD (Million)
        • 9.4.1.5.2. Erectile Dysfunction (ED) Drugs Market: By Distribution Channel, 2023-2033, USD (Million)
      • 9.4.1.6. Rest of Asia Pacific
        • 9.4.1.6.1. Erectile Dysfunction (ED) Drugs Market: By Drug, 2023-2033, USD (Million)
        • 9.4.1.6.2. Erectile Dysfunction (ED) Drugs Market: By Distribution Channel, 2023-2033, USD (Million)

10. Latin America Erectile Dysfunction (ED) Drugs Market, 2023-2033, USD (Million)

  • 10.1. Market Overview
  • 10.2. Erectile Dysfunction (ED) Drugs Market: By Drug, 2023-2033, USD (Million)
  • 10.3. Erectile Dysfunction (ED) Drugs Market: By Distribution Channel, 2023-2033, USD (Million)
  • 10.4.Erectile Dysfunction (ED) Drugs Market: By Region, 2023-2033, USD (Million)
    • 10.4.1.Latin America
      • 10.4.1.1. Brazil
        • 10.4.1.1.1. Erectile Dysfunction (ED) Drugs Market: By Drug, 2023-2033, USD (Million)
        • 10.4.1.1.2. Erectile Dysfunction (ED) Drugs Market: By Distribution Channel, 2023-2033, USD (Million)
      • 10.4.1.2. Mexico
        • 10.4.1.2.1. Erectile Dysfunction (ED) Drugs Market: By Drug, 2023-2033, USD (Million)
        • 10.4.1.2.2. Erectile Dysfunction (ED) Drugs Market: By Distribution Channel, 2023-2033, USD (Million)
      • 10.4.1.3. Rest of Latin America
        • 10.4.1.3.1. Erectile Dysfunction (ED) Drugs Market: By Drug, 2023-2033, USD (Million)
        • 10.4.1.3.2. Erectile Dysfunction (ED) Drugs Market: By Distribution Channel, 2023-2033, USD (Million)

11. Middle East and Africa Erectile Dysfunction (ED) Drugs Market, 2023-2033, USD (Million)

  • 11.1. Market Overview
  • 11.2. Erectile Dysfunction (ED) Drugs Market: By Drug, 2023-2033, USD (Million)
  • 11.3. Erectile Dysfunction (ED) Drugs Market: By Distribution Channel, 2023-2033, USD (Million)
  • 11.4.Erectile Dysfunction (ED) Drugs Market: By Region, 2023-2033, USD (Million)
    • 11.4.1.Middle East and Africa
      • 11.4.1.1. GCC
        • 11.4.1.1.1. Erectile Dysfunction (ED) Drugs Market: By Drug, 2023-2033, USD (Million)
        • 11.4.1.1.2. Erectile Dysfunction (ED) Drugs Market: By Distribution Channel, 2023-2033, USD (Million)
      • 11.4.1.2. Africa
        • 11.4.1.2.1. Erectile Dysfunction (ED) Drugs Market: By Drug, 2023-2033, USD (Million)
        • 11.4.1.2.2. Erectile Dysfunction (ED) Drugs Market: By Distribution Channel, 2023-2033, USD (Million)
      • 11.4.1.3. Rest of Middle East and Africa
        • 11.4.1.3.1. Erectile Dysfunction (ED) Drugs Market: By Drug, 2023-2033, USD (Million)
        • 11.4.1.3.2. Erectile Dysfunction (ED) Drugs Market: By Distribution Channel, 2023-2033, USD (Million)

12. Company Profile

  • 12.1. Pfizer, Inc.
    • 12.1.1. Company Overview
    • 12.1.2. Financial Performance
    • 12.1.3. Product Portfolio
    • 12.1.4. Strategic Initiatives
  • 12.2. Dong-A ST Co., Ltd.
    • 12.2.1. Company Overview
    • 12.2.2. Financial Performance
    • 12.2.3. Product Portfolio
    • 12.2.4. Strategic Initiatives
  • 12.3. Eli Lilly and Company
    • 12.3.1. Company Overview
    • 12.3.2. Financial Performance
    • 12.3.3. Product Portfolio
    • 12.3.4. Strategic Initiatives
  • 12.4. Bayer AG
    • 12.4.1. Company Overview
    • 12.4.2. Financial Performance
    • 12.4.3. Product Portfolio
    • 12.4.4. Strategic Initiatives
  • 12.5. Vivus, Inc.
    • 12.5.1. Company Overview
    • 12.5.2. Financial Performance
    • 12.5.3. Product Portfolio
    • 12.5.4. Strategic Initiatives
  • 12.6. Teva Pharmaceutical Industries Ltd.
    • 12.6.1. Company Overview
    • 12.6.2. Financial Performance
    • 12.6.3. Product Portfolio
    • 12.6.4. Strategic Initiatives
  • 12.7. SK Chemicals
    • 12.7.1. Company Overview
    • 12.7.2. Financial Performance
    • 12.7.3. Product Portfolio
    • 12.7.4. Strategic Initiatives
  • 12.8. Meda Pharmaceuticals, Inc.
    • 12.8.1. Company Overview
    • 12.8.2. Financial Performance
    • 12.8.3. Product Portfolio
    • 12.8.4. Strategic Initiatives
  • 12.9. Cristalia Produtos Quimicos Farmaceuticos Ltda. Apricus Biosciences, Inc.
    • 12.9.1. Company Overview
    • 12.9.2. Financial Performance
    • 12.9.3. Product Portfolio
    • 12.9.4. Strategic Initiatives
  • 12.10. Futura Medical plc
    • 12.10.1. Company Overview
    • 12.10.2. Financial Performance
    • 12.10.3. Product Portfolio
    • 12.10.4. Strategic Initiatives
  • 12.11. Other prominent players
    • 12.11.1. Company Overview
    • 12.11.2. Financial Performance
    • 12.11.3. Product Portfolio
    • 12.11.4. Strategic Initiatives

List of Tables

  • TABLE 1 Global Erectile Dysfunction (ED) Drugs Market By Drug, 2023-2033, USD (Million)
  • TABLE 2 Global Erectile Dysfunction (ED) Drugs Market By Distribution Channel, 2023-2033, USD (Million)
  • TABLE 3 North America Erectile Dysfunction (ED) Drugs Market By Drug, 2023-2033, USD (Million)
  • TABLE 4 North America Erectile Dysfunction (ED) Drugs Market By Distribution Channel, 2023-2033, USD (Million)
  • TABLE 5 U.S. Erectile Dysfunction (ED) Drugs Market By Drug, 2023-2033, USD (Million)
  • TABLE 6 U.S. Erectile Dysfunction (ED) Drugs Market By Distribution Channel, 2023-2033, USD (Million)
  • TABLE 7 Canada Erectile Dysfunction (ED) Drugs Market By Drug, 2023-2033, USD (Million)
  • TABLE 8 Canada Erectile Dysfunction (ED) Drugs Market By Distribution Channel, 2023-2033, USD (Million)
  • TABLE 9 Rest of North America Erectile Dysfunction (ED) Drugs Market By Drug, 2023-2033, USD (Million)
  • TABLE 10 Rest of North America Erectile Dysfunction (ED) Drugs Market By Distribution Channel, 2023-2033, USD (Million)
  • TABLE 11 UK and European Union Erectile Dysfunction (ED) Drugs Market By Drug, 2023-2033, USD (Million)
  • TABLE 12 UK and European Union Erectile Dysfunction (ED) Drugs Market By Distribution Channel, 2023-2033, USD (Million)
  • TABLE 13 UK Erectile Dysfunction (ED) Drugs Market By Drug, 2023-2033, USD (Million)
  • TABLE 14 UK Erectile Dysfunction (ED) Drugs Market By Distribution Channel, 2023-2033, USD (Million)
  • TABLE 15 Germany Erectile Dysfunction (ED) Drugs Market By Drug, 2023-2033, USD (Million)
  • TABLE 16 Germany Erectile Dysfunction (ED) Drugs Market By Distribution Channel, 2023-2033, USD (Million)
  • TABLE 17 Spain Erectile Dysfunction (ED) Drugs Market By Drug, 2023-2033, USD (Million)
  • TABLE 18 Spain Erectile Dysfunction (ED) Drugs Market By Distribution Channel, 2023-2033, USD (Million)
  • TABLE 19 Italy Erectile Dysfunction (ED) Drugs Market By Drug, 2023-2033, USD (Million)
  • TABLE 20 Italy Erectile Dysfunction (ED) Drugs Market By Distribution Channel, 2023-2033, USD (Million)
  • TABLE 21 France Erectile Dysfunction (ED) Drugs Market By Drug, 2023-2033, USD (Million)
  • TABLE 22 France Erectile Dysfunction (ED) Drugs Market By Distribution Channel, 2023-2033, USD (Million)
  • TABLE 23 Rest of Europe Erectile Dysfunction (ED) Drugs Market By Drug, 2023-2033, USD (Million)
  • TABLE 24 Rest of Europe Erectile Dysfunction (ED) Drugs Market By Distribution Channel, 2023-2033, USD (Million)
  • TABLE 25 Asia Erectile Dysfunction (ED) Drugs Market By Drug, 2023-2033, USD (Million)
  • TABLE 26 Asia Erectile Dysfunction (ED) Drugs Market By Distribution Channel, 2023-2033, USD (Million)
  • TABLE 27 China Erectile Dysfunction (ED) Drugs Market By Drug, 2023-2033, USD (Million)
  • TABLE 28 China Erectile Dysfunction (ED) Drugs Market By Distribution Channel, 2023-2033, USD (Million)
  • TABLE 29 Japan Erectile Dysfunction (ED) Drugs Market By Drug, 2023-2033, USD (Million)
  • TABLE 30 Japan Erectile Dysfunction (ED) Drugs Market By Distribution Channel, 2023-2033, USD (Million)
  • TABLE 31 India Erectile Dysfunction (ED) Drugs Market By Drug, 2023-2033, USD (Million)
  • TABLE 32 India Erectile Dysfunction (ED) Drugs Market By Distribution Channel, 2023-2033, USD (Million)
  • TABLE 33 Australia Erectile Dysfunction (ED) Drugs Market By Drug, 2023-2033, USD (Million)
  • TABLE 34 Australia Erectile Dysfunction (ED) Drugs Market By Distribution Channel, 2023-2033, USD (Million)
  • TABLE 35 South Korea Erectile Dysfunction (ED) Drugs Market By Drug, 2023-2033, USD (Million)
  • TABLE 36 South Korea Erectile Dysfunction (ED) Drugs Market By Distribution Channel, 2023-2033, USD (Million)
  • TABLE 37 Latin America Erectile Dysfunction (ED) Drugs Market By Drug, 2023-2033, USD (Million)
  • TABLE 38 Latin America Erectile Dysfunction (ED) Drugs Market By Distribution Channel, 2023-2033, USD (Million)
  • TABLE 39 Brazil Erectile Dysfunction (ED) Drugs Market By Drug, 2023-2033, USD (Million)
  • TABLE 40 Brazil Erectile Dysfunction (ED) Drugs Market By Distribution Channel, 2023-2033, USD (Million)
  • TABLE 41 Mexico Erectile Dysfunction (ED) Drugs Market By Drug, 2023-2033, USD (Million)
  • TABLE 42 Mexico Erectile Dysfunction (ED) Drugs Market By Distribution Channel, 2023-2033, USD (Million)
  • TABLE 43 Rest of Latin America Erectile Dysfunction (ED) Drugs Market By Drug, 2023-2033, USD (Million)
  • TABLE 44 Rest of Latin America Erectile Dysfunction (ED) Drugs Market By Distribution Channel, 2023-2033, USD (Million)
  • TABLE 45 Middle East and Africa Erectile Dysfunction (ED) Drugs Market By Drug, 2023-2033, USD (Million)
  • TABLE 46 Middle East and Africa Erectile Dysfunction (ED) Drugs Market By Distribution Channel, 2023-2033, USD (Million)
  • TABLE 47 GCC Erectile Dysfunction (ED) Drugs Market By Drug, 2023-2033, USD (Million)
  • TABLE 48 GCC Erectile Dysfunction (ED) Drugs Market By Distribution Channel, 2023-2033, USD (Million)
  • TABLE 49 Africa Erectile Dysfunction (ED) Drugs Market By Drug, 2023-2033, USD (Million)
  • TABLE 50 Africa Erectile Dysfunction (ED) Drugs Market By Distribution Channel, 2023-2033, USD (Million)
  • TABLE 51 Rest of Middle East and Africa Erectile Dysfunction (ED) Drugs Market By Drug, 2023-2033, USD (Million)
  • TABLE 52 Rest of Middle East and Africa Erectile Dysfunction (ED) Drugs Market By Distribution Channel, 2023-2033, USD (Million)

List of Figures

  • FIG. 1 Global Erectile Dysfunction (ED) Drugs Market: Market Coverage
  • FIG. 2 Research Methodology and Data Sources
  • FIG. 3 Market Size Estimation - Top Down & Bottom-Up Approach
  • FIG. 4 Global Erectile Dysfunction (ED) Drugs Market: Quality Assurance
  • FIG. 5 Global Erectile Dysfunction (ED) Drugs Market, By Drug, 2024
  • FIG. 6 Global Erectile Dysfunction (ED) Drugs Market, By Distribution Channel, 2024
  • FIG. 7 Global Erectile Dysfunction (ED) Drugs Market, By Geography, 2024
  • FIG. 8 Market Geographical Opportunity Matrix - Global Erectile Dysfunction (ED) Drugs Market, 2024
  • FIG. 9Market Positioning of Key Erectile Dysfunction (ED) Drugs Market Players, 2024
  • FIG. 10 Global Erectile Dysfunction (ED) Drugs Market, By Drug, 2024 Vs 2033, %
  • FIG. 11 Global Erectile Dysfunction (ED) Drugs Market, By Distribution Channel, 2024 Vs 2033, %